Risk Stratification and Cardiac Sympathetic Activity Assessment Using Myocardial [123I] MIBG Imaging in Renal...

Area of Science:

• Cardiology
• Nuclear Medicine
• Hypertension Research

Background:

• Sympathetic nervous system hyperactivity is key in hypertension pathophysiology.
• Resistant hypertension requires advanced treatment strategies like renal denervation (RDN).
• Assessing cardiac sympathetic activity aids cardiovascular risk stratification.

Purpose of the Study:

• To evaluate cardiac sympathetic activity using myocardial [123I] MIBG scintigraphy.
• To investigate the role of [123I] MIBG scintigraphy in risk stratification for resistant hypertension patients undergoing RDN.
• To correlate [123I] MIBG parameters with response to RDN.

Main Methods:

• Prospective study of 18 resistant hypertension patients undergoing RDN.
• Transthoracic echocardiogram, blood analysis, and myocardial [123I] MIBG scintigraphy performed pre- and post-RDN.
• Patients categorized as responders (≥5mmHg systolic BP drop) or non-responders at 6 months.

Main Results:

• RDN effectively lowered systolic BP in 66.7% of patients.
• Lower baseline early heart-mediastinum ratio (HMR) observed in responders vs. non-responders.
• [123I] MIBG parameters did not predict RDN response; no significant correlation found.

Conclusions:

• RDN is effective in lowering blood pressure in resistant hypertension.
• [123I] MIBG scintigraphy is not a reliable predictor of RDN treatment response.
• Reduced HMR suggests sympathetic overdrive, potentially indicating higher cardiovascular risk in this population.